Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus
This article was originally published in The Pink Sheet Daily
Lechleiter editorial, Chamber of Commerce appearance include warnings about adverse effects on innovation; “Odyssey Project” launched to press similar themes.
You may also be interested in...
Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.
The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.
A US FDA advisory committee review of a novel COVID vaccine candidate from Novavax made one thing very clear: The agency is firmly convinced that when it comes to vaccine options, more is better.